Geographical clustering of cases of infection with moxifloxacin-resistant Clostridium difficile PCR-ribotypes 012, 017 and 046 in Sweden, 2008 and 2009

被引:0
作者
Akerlund, T. [1 ]
Alefjord, I. [1 ]
Dohnhammar, U. [1 ]
Struwe, J. [1 ]
Noren, T. [2 ]
Tegmark-Wisell, K. [1 ]
机构
[1] Swedish Inst Infect Dis Control, Solna, Sweden
[2] Orebro Univ Hosp, Dept Infect Dis, Orebro, Sweden
关键词
MOLECULAR CHARACTERIZATION; EPIDEMIOLOGY; DISEASE; FLUOROQUINOLONES; EMERGENCE; SUSCEPTIBILITY; PREVALENCE; OUTBREAKS; STRAIN; PIGS;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We report the results of two nationwide surveillance studies of Clostridium difficile infection conducted during 2008 and 2009 in Sweden. The first study aimed to identify and quantify the proportion of C. difficile isolates with decreased susceptibility to moxifloxacin, particularly those of PCR-ribotype 027. From December 2007 to September 2008, 20 of 28 regional laboratories sent 585 isolates to the Swedish Institute for Infectious Disease Control for typing. A majority of the isolates (454 of 585; 78%) belonged to four PCR ribotypes (012, SE37, 017 and 046), all clustered in geographical regions. Only two type 027 isolates were found, both from the same patient. In the second study, involving all 28 regional laboratories, all consecutive C. difficile isolates collected during two time periods in 2009 (n=364) were typed and tested for susceptibility to clindamycin, erythromycin, moxifloxacin, metronidazole and vancomycin. The three most common PCR ribotypes were SE21, 001 and 020 (22% of all isolates). Types 012, 017, and 046 were geographically clustered and associated with decreased susceptibility to moxifloxacin, clindamycin and erythromcin. The extent of moxifloxacin prescription was highly variable among counties, indicating a need for careful monitoring of prescription rates to follow its role in C. difficile epidemiology.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 38 条
  • [1] Increased sporulation rate of epidemic clostridium difficile type 027/NAP1
    Akerlund, Thomas
    Persson, Ingela
    Unemo, Magnus
    Noren, Torbjoern
    Svenungsson, Bo
    Wullt, Marlene
    Burman, Lars G.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (04) : 1530 - 1533
  • [2] Bacci S, 2009, EUROSURVEILLANCE, V14, P4
  • [3] Clostridium difficile infection in Europe: a hospital-based survey
    Bauer, Martijn P.
    Notermans, Daan W.
    van Benthem, Birgit H. B.
    Brazier, Jon S.
    Wilcox, Mark H.
    Rupnik, Maja
    Monnet, Dominique L.
    van Dissel, Jaap T.
    Kuijper, Ed J.
    [J]. LANCET, 2011, 377 (9759) : 63 - 73
  • [4] Moxifloxacin therapy as a risk factor for clostridium difficile-associated disease during an outbreak: Attempts to control a new epidemic strain
    Biller, Priscilla
    Shank, Beth
    Lind, Leah
    Brennan, Meghan
    Tkatch, Lisa
    Killgore, George
    Thompson, Angela
    McDonald, L. Clifford
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2007, 28 (02) : 198 - 201
  • [5] Birgand G, 2010, EURO SURVEILL, V15
  • [6] BORGMANN S, 2008, EURO SURVEILL, V13
  • [7] Brazier J S, 2008, Euro Surveill, V13
  • [8] Typing of Clostridium difficile
    Brazier, JS
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (08) : 428 - 431
  • [9] Impact of different empirical antibiotic treatment regimens for community-acquired pneumonia on the emergence of Clostridium difficile
    Bruns, Anke H. W.
    Oosterheert, Jan Jelrik
    Kuijper, Ed J.
    Lammers, Jan Willem J.
    Thijsen, Steven
    Troelstra, Annet
    Hoepelman, Andy I. M.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (11) : 2464 - 2471
  • [10] Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread
    Clements, Archie C. A.
    Magalhaes, Ricardo J. Soares
    Tatem, Andrew J.
    Paterson, David L.
    Riley, Thomas V.
    [J]. LANCET INFECTIOUS DISEASES, 2010, 10 (06) : 395 - 404